Case report highlights multimodal pain care in canine urothelial carcinoma
Bottom line
A new peer-reviewed case report in Today’s Veterinary Nurse walks through multimodal pain management for a dog diagnosed with advanced, metastatic invasive urothelial carcinoma, highlighting how supportive care was structured when cure was no longer the realistic goal. The report centers on a patient with late-stage disease at diagnosis, a common and difficult scenario in canine urothelial carcinoma, which is locally invasive, prone to metastasis, and associated with urinary obstruction risk and substantial pain burden. Broader oncology guidance from AAHA and WSAVA also underscores that cancer care in dogs is typically multimodal, with pain control and quality-of-life support treated as core parts of case management, not secondary concerns. (aaha.org)
Why it matters: For veterinary professionals, the value of this case is practical. Canine urothelial carcinoma often presents at an advanced stage, and published reviews suggest metastasis is already evident in about 20% of dogs at diagnosis, with worse prognosis once distant spread is present. In that setting, nursing observation, serial pain assessment, caregiver coaching, and layered analgesia become central to maintaining comfort and function. The case also lands as the profession continues to put more emphasis on supportive oncology care, including structured palliative planning, early analgesic intervention, and realistic communication with pet parents about goals, tradeoffs, and quality of life. (sciencedirect.com)
What to watch: Expect continued interest in palliative-intent protocols for canine urothelial carcinoma, including combinations of analgesics, NSAID-based therapy, and radiation approaches aimed at preserving comfort and urinary function. (pmc.ncbi.nlm.nih.gov)
Key facts
- Article type
- Peer-reviewed case report
- Journal
- Today’s Veterinary Nurse
- Patient
- Dog with metastatic invasive urothelial carcinoma
- Stage at diagnosis
- Advanced stage
- Clinical focus
- Multimodal pain management
- Disease behavior
- Locally invasive, prone to metastasis, and associated with urinary obstruction risk
- Care goal
- Supportive care when cure was no longer the realistic goal
- Guidance cited
- AAHA and WSAVA support multimodal cancer pain care and quality-of-life support
A new peer-reviewed case report in Today’s Veterinary Nurse focuses on multimodal pain management for a dog with metastatic invasive urothelial carcinoma, offering a nursing-centered look at how comfort care can be built for a patient diagnosed at an advanced stage. While the article is framed as a single-patient case, it speaks to a broader reality in practice: many dogs with invasive urothelial carcinoma arrive with extensive disease, limited curative options, and an immediate need for symptom control and quality-of-life planning. (frontiersin.org)
That context matters because canine urothelial carcinoma is both common within the urinary tract and clinically challenging. AAHA’s 2026 oncology guidance describes it as an aggressive cancer with a tendency toward local invasion, regional and distant metastasis, and urinary tract obstruction. Reviews of the disease have long noted that complete surgical management is often not feasible because of tumor location and urethral involvement, which pushes many cases toward medical, palliative, or multimodal management instead. (aaha.org)
The case report’s emphasis on multimodal analgesia also aligns with current oncology and pain guidance. AAHA states that supportive and symptomatic care are essential components of oncology management, with the goal of maintaining or improving quality of life throughout treatment. WSAVA guidance similarly recommends a multimodal drug approach for chronic cancer pain, especially because cancer pain can include inflammatory, neuropathic, and procedure-related components at the same time. In practical terms, that means teams often need to combine tumor-directed therapy with layered symptom control rather than rely on a single intervention. (aaha.org)
There’s also disease-specific rationale for that approach in urothelial carcinoma. Published reviews note that NSAIDs have an established role in canine urothelial carcinoma not only for analgesia, but also because this tumor type appears particularly responsive to COX inhibition. One recent review summarized prior reports showing remission rates of roughly 18% to 20% with piroxicam alone and median survival times in the range of about 152 to 323 days in some series. Another study reported median survival of 151 days for dogs treated with meloxicam alone, similar to historical piroxicam-only outcomes, while combination therapy with chemotherapy may improve tumor response at the cost of added adverse-event risk. (onlinelibrary.wiley.com)
Industry and expert commentary around veterinary oncology has increasingly reinforced the same message: palliative care is not just end-stage care, and pain control should start early. A recent review of veterinary palliative care argues that many dogs and cats with cancer have likely experienced pain before diagnosis, and that teams should be proactive in recognizing and relieving it. Another review on cancer pain management says multimodal analgesic plans generally offer advantages over single-agent therapy for outcome and risk balance. For nurses and technicians, that translates into a larger role in monitoring appetite, mobility, elimination, medication tolerance, and day-to-day comfort, while helping pet parents understand how to judge whether a plan is still meeting the patient’s needs. (vetmed.agriculturejournals.cz)
Why it matters: This is the kind of case report that can influence care well beyond one patient. In advanced urothelial carcinoma, the clinical challenge is often less about selecting a single “best” treatment and more about coordinating a realistic package of care: analgesics, anti-inflammatory therapy, possible chemotherapy, possible palliative radiation, urinary support, monitoring for obstruction, and frequent reassessment. That requires tight collaboration between veterinarians and nursing staff, plus clear communication with pet parents about expected progression, adverse effects, and quality-of-life thresholds. The report fits squarely within a broader shift in oncology toward supportive care as a clinical discipline, rather than an afterthought. (aaha.org)
There may also be a forward-looking angle here. Radiation therapy is drawing renewed attention in canine urothelial carcinoma, including for palliation of obstruction and local symptoms. A 2026 retrospective report from Colorado State University found that both palliative- and definitive-intent radiation protocols reduced obstruction time, with better outcomes when chemotherapy was given concurrently. That doesn’t make radiation appropriate for every patient, but it suggests that pain and comfort discussions in metastatic urothelial carcinoma are increasingly tied to preserving urinary function as well as reducing suffering. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for more case-based and protocol-driven reporting on supportive oncology, especially around how teams combine NSAIDs, adjunctive analgesics, chemotherapy, and palliative radiation for dogs with late-stage urothelial carcinoma, as well as more formal research priorities in veterinary palliative care. (sciencedirect.com)